Companies: 10,795·Total market cap: $144.5T
Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc.

APVONASDAQHealthcare● Active
$4.89
+$0.17(+3.60%)
Market Cap$10693731
P/E Ratio—
52W High$235.98
52W Low$3.8
SEC Filings

Aptevo Therapeutics Inc. (APVO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001671584 · APVO · NASDAQ · as of Jun 9, 2026

Filing snapshot

700
Total Filings
3
Latest Form
2026-05-28
Most Recent
2016
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001671584 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-26
Fiscal Year End
Mar 26, 2026
Accession No.
0001193125-26-126278
Primary Document
apvo-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001671584 · Accession 0001193125-26-126278

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-13
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-27Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
3Initial Statement of Beneficial Ownership
3
2026-05-28
View
8-KCurrent Report
8-K
2026-05-27
View
10-QQuarterly Report
10-Q
2026-05-13
View
8-KCurrent Report
8-K
2026-05-13
View
8-KCurrent Report
8-K
2026-05-06
View
10-KAnnual Report
10-K
2026-03-26
View
8-KCurrent Report
8-K
2026-03-26
View
8-KCurrent Report
8-K
2026-03-11
View
8-KCurrent Report
8-K
2026-02-19
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
8-KCurrent Report
8-K
2026-02-03
View
EFFECTEFFECT
EFFECT
2026-01-30
View
424B4424B4
424B4
2026-01-30
View
CORRESPCORRESP
CORRESP
2026-01-29
View
Showing 1–15 of 471 filingsForm 4 / 144 hidden· 700 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001671584  |  Exchange: NASDAQ · Healthcare

Aptevo Therapeutics Inc. (NASDAQ: APVO) has submitted 700 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2016. As a Healthcare sector company with CIK 0001671584, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aptevo Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent Aptevo Therapeutics Inc. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical APVO 10-K annual reports are available from 2016 through 2026.

Investors researching Aptevo Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
KPRX SEC Filings →EPIX SEC Filings →INAB SEC Filings →RADX SEC Filings →BCDA SEC Filings →MTNB SEC Filings →HCWB SEC Filings →ERNA SEC Filings →
→ APVO Financials→ APVO Earnings→ APVO Insider Trades

Frequently Asked Questions

APVO SEC Filings · 8 questions

Aptevo Therapeutics Inc. (APVO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 700 filings and access original documents at no cost. Aptevo Therapeutics Inc.'s CIK is 0001671584.

APVO SEC filingsAptevo Therapeutics Inc. SEC documentsfind APVO 10-K